Market closedNon-fractional

Relmada Therapeutics/RLMD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Ticker

RLMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Coral Gables, United States

Employees

20

RLMD Metrics

BasicAdvanced
$125M
Market cap
-
P/E ratio
-$3.13
EPS
0.27
Beta
-
Dividend rate
$125M
0.27
6.825
6.764
-55.99%
-95.48%
1.74
1.74
-2.586
-34.45%
-10.87%

What the Analysts think about RLMD

Analyst Ratings

Majority rating from 5 analysts.
Hold

RLMD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
-13.15%
Profit margin
0.00%
NaN%

RLMD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.23%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.84
-$0.73
-$0.84
-$0.72
-
Expected
-$0.90
-$0.91
-$0.83
-$0.85
-$0.83
Surprise
-6.34%
-20.04%
1.20%
-15.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Relmada Therapeutics stock?

Relmada Therapeutics (RLMD) has a market cap of $125M as of July 23, 2024.

What is the P/E ratio for Relmada Therapeutics stock?

The price to earnings (P/E) ratio for Relmada Therapeutics (RLMD) stock is 0 as of July 23, 2024.

Does Relmada Therapeutics stock pay dividends?

No, Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Relmada Therapeutics dividend payment date?

Relmada Therapeutics (RLMD) stock does not pay dividends to its shareholders.

What is the beta indicator for Relmada Therapeutics?

Relmada Therapeutics (RLMD) has a beta rating of 0.27. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Relmada Therapeutics stock

Buy or sell Relmada Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing